VistaGen Therapeutics, Inc.
http://www.vistagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VistaGen Therapeutics, Inc.
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
VistaGen Hopes To Bounce Back With Spray-Based Depression Drug
NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- VistaStem Therapeutics, Inc.